Newmanbrain’s innovation makes it easier for healthcare professionals to detect neurological and mental disorders such as cognitive impairment of aging or ADHD in children.
Improve patient health through more accurate diagnosis of brain and mental illnesses such as depression, hyperactivity, dementia or addictions.
With this objective, the spin-off Newmanbrain of the UMH Science Park (PCUMH) in Elche (Alicante) has developed THEIA™.
THEIA™ is a portable device that using fNIRs (functional near-infrared spectroscopy) technology measures brain activity non-invasively and has already been tested on more than 600 people.
“We are the first to have built a patented system that is scientifically proven to work.” Highlights Pablo Belmonte, CEO of Newmanbrain.
The development of Newmanbrain makes it easier for the healthcare professional to detect cognitive disorders, such as those associated with aging or ADHD in children.
“Through Artificial Intelligence and functional near-infrared spectroscopy (fNIRs), our system allows us to obtain a series of data on brain function. Once sent to the cloud and analyzed by our team of professionals, they are converted into a report that helps the physician to make a decision on the diagnosis,” says Pablo Belmonte.
Professional capital
Newmanbrain has already raised professional capital and now its main goal is to make its technology “improve the lives of millions of human beings around the world”.
Health and Artificial Intelligence
Newmanbrain, which is currently focused on its innovative development of diagnosis and treatment, has set itself the goal of “optimizing Artificial Intelligence algorithms, in order to accurately diagnose various brain pathologies”.
With the development of THEIA™, Newmanbrain wants to provide an answer to a problem faced by scientists studying brain functions: the lack of data underlying neural processes and tools to evidence the correlation between the activity of brain areas and the mental functions attributed to each area (cognitive processes, emotions, physical sensations and basic motor functions, etc.).
“The premise is that finding this linkage will allow scientists to better understand human behavior and facilitate its objective assessment.”
Recently, in order to showcase its innovation and respond to the challenges and solutions that arise in the field of healthcare when applying AI, the company participated in the event “Artificial Intelligence applied to Hospital Management: challenges and opportunities”, organized by the Torre Juana OST technology space. During the meeting, Pablo Belmonte CEO of Newmanbrain and Dr. Joaquín Ibáñez Co-founder & CSO of the company, had the opportunity to participate in a conference on use cases and demonstration of tools in which they presented the applications and benefits of its THEIA™ system.
Newmanbrain is a spin-off focused on the development of software and hardware for biomedical applications in the fields of neuroscience and biomedicine. The company is driven by the former director of the Instituto de Neurociencias (IN), a joint center between the UMH and the Consejo Superior de Investigaciones Científicas (CSIC), and professor emeritus of the UMH, Dr. Carlos Belmonte, by the engineer Alejandro Méndez, by the director of the Department of Physiology of the UMH, Dr. Joaquín Ibáñez, and by Pablo Belmonte, CEO of the firm.
Fonts:
Parque Científico de la UMH, ABC, La Vanguardia, La Voz Digital, Europa Press